Sionna Therapeutics, Inc. Common Stock reports a Return on Equity (ROE) of -29.69%.

What is SION's dividend yield?

Sionna Therapeutics, Inc. Common Stock offers a dividend yield of 0.00%.

What is SION's Quality Score?

Our AI rates SION's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy SION?

Our AI Timing Score for SION is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does SION belong to?

Sionna Therapeutics, Inc. Common Stock is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Sionna Therapeutics, Inc. (SION) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-03 | FS: 2026-03-31)

SION AI Analysis Summary

Our AI summary for SION: Sionna Therapeutics, Inc. Common Stock (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -29.69%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

SION

Sionna Therapeutics, Inc. Common Stock

US:NASDAQ STOCK Healthcare >> Biotechnology

USD 49.26

0.68 (1.38%) Day Change

Watchlist Portfolio Compare Chart

0.00

D/E

-29.7%

ROE

-28.1%

ROA

0.00%

Div Yield

SIONNA THERAPEUTICS, INC. COMMON STOCK
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 49.26 Price 0.68 (1.38%) Day Change	NEWS SCORE: N/A

SION, the overall quality is not good ( Quality = 23) but the timing to buy is ...(Sign In to See)...

Loading chart...

23 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

42%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	49.26
PBV / Sector	7.38 / 44,219.29
Earning Per Share	-1.98

PE / Sector	N/A / 19.28
PEG or PE/Growth / Sector	N/A / 1.23
Average 1M Daily Value	26.70 M GREAT
Average 1W Daily Value	24.27 M GREAT

Timing Factors

85%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.22
NPM Average (%) / Sector	N/A / -1,697.63
NPM Change Average (%) / Sector	N/A / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-28.05 / 185,260.96
ROA Average (%) / Sector	-44.28 / 36,684.70
ROA Change Average (%) / Sector	6.26 / 422,221.66
ROE (%) / Sector	-29.69 / 243,762.23
ROE Average (%) / Sector	16.43 / 48,758.47
ROE Change Average (%) / Sector	-45.25 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.19

Registration Details

Analyze Date	2026-08-04 08:02:09
Symbol	SION
Name	SIONNA THERAPEUTICS, INC. COMMON STOCK
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	45.15 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	2,127.93 / 9,645.64

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 21 Hickory Drive, Waltham, MA, United States, 02451

Phone: 617 819 2020

Website: https://www.sionnatx.com

Employees: 59

Sector: Healthcare >> Biotechnology

Description: Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.